Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma

NCT00390325 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00390325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00390325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
November 3, 2006
Completion date
December 22, 2022
Enrollment
21 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary thyroid gland medullary carcinoma, locally advanced thyroid gland medullary carcinoma, multiple endocrine neoplasia type 2a, multiple endocrine neoplasia type 2b, recurrent thyroid gland medullary carcinoma, sporadic thyroid gland medullary carcinoma, stage iii thyroid gland medullary carcinoma ajcc v7, stage iv thyroid gland medullary carcinoma ajcc v7, stage iva thyroid gland medullary carcinoma ajcc v7, stage ivb thyroid gland medullary carcinoma ajcc v7, stage ivc thyroid gland medullary carcinoma ajcc v7